17 September 2025
17 September 2025
The investment includes a $1.2bn package for advanced manufacturing, AI and digital technologies.
The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over the next five years.
The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.
As part of the collaboration, CSL will fully finance the Phase III EquilibriX-S trial of VMX-C001.
Novartis has joined the swathe of big pharma companies bolstering their molecular glue degrader portfolios.
The British drugmaker shelved a separate £450m ($612m) investment in a vaccine manufacturing plant in northern England, earlier this year.
The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over the next five years.
The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
